Search

Ovid therapeutics Inc

Gesloten

SectorGezondheidszorg

2.58 -5.15

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.57

Max

2.81

Belangrijke statistieken

By Trading Economics

Inkomsten

-27M

-17M

EPS

-0.125

Winstmarge

-2,366.017

Werknemers

23

EBITDA

-4.7M

-17M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+105.13% upside

Dividenden

By Acuity

Volgende Winsten

12 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

4.4M

487M

Vorige openingsprijs

7.73

Vorige sluitingsprijs

2.58

Ovid therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

9 jul 2026, 23:56 UTC

Social Media
News

NVIDIA Corp shares are lower in after-market trading amid concerns about its AI sector performance and intensifying competition from other chip manufacturers.

9 jul 2026, 23:51 UTC

News
Social Media

Meta Platforms Inc. shares advanced in after-market trading following the launch of Muse Spark 1.1, an AI model aimed at enhancing software development capabilities.

9 jul 2026, 23:51 UTC

Social Media
News

Netflix is exploring strategies to boost subscriber engagement amid declining viewer interest. Shares fell in after-hours trading following these developments.

9 jul 2026, 23:46 UTC

News

The United States Oil Fund LP is trading lower in after-market hours, reflecting ongoing geopolitical tensions and a flat trajectory since Thursday's close.

9 jul 2026, 23:36 UTC

News

Starbucks is developing AI tools to save $2 billion, including $400 million in software costs. Shares are higher in after-market trading.

9 jul 2026, 23:16 UTC

News

Micron Technology expands U.S. investment to $250 billion by 2035, boosting capital expenditures by $50 billion. Shares rise in after-market trading.

9 jul 2026, 23:06 UTC

Social Media
News

Tesla shares declined in after-market trading following a Hold rating from Citizens' Andrew Boone, who cited caution on the company's AI timeline.

9 jul 2026, 20:07 UTC

News

BMO Capital initiated coverage on Align Technology with an Outperform rating and a price target of $209, contributing to positive sentiment despite leadership changes.

9 jul 2026, 20:07 UTC

Correlated Moves
News

The iShares Core U.S. Aggregate Bond ETF is advancing today, supported by a decline in Treasury yields and positive labor market data.

9 jul 2026, 20:07 UTC

ETF Constituents
Correlated Moves
News
Social Media

SPDR S&P 500 ETF Trust advances amid mixed market sentiment and geopolitical tensions. Initial jobless claims fell to 215,000, supporting positive momentum.

9 jul 2026, 20:07 UTC

ETF Constituents
Correlated Moves
News
Social Media

The iShares Russell 2000 ETF is gaining amid geopolitical tensions and positive economic indicators, despite earlier fluctuations in the session.

9 jul 2026, 20:07 UTC

Social Media
News
Correlated Moves
Macro Event

The iShares iBoxx $ Investment Grade Corporate Bond ETF and iShares TIPS Bond ETF are trading higher, supported by falling Treasury yields and improved jobless claims.

9 jul 2026, 20:07 UTC

News
Social Media

Alphabet Inc. shares are lower amid concerns about its AI competitiveness, as a report suggests Meta may surpass Google in frontier AI capabilities.

9 jul 2026, 20:07 UTC

Social Media
Correlated Moves
News

Western Digital shares rise as Micron plans $250 billion investment in U.S. memory production, boosting demand and pricing in the memory chip sector.

9 jul 2026, 20:07 UTC

Correlated Moves
Social Media
Macro Event
News

Applied Materials shares advanced on analyst target increases amid strong demand outlook. The Nasdaq 100's rise also supported the stock's performance.

9 jul 2026, 20:07 UTC

Social Media
News
Correlated Moves

Broadcom Inc gains as it joins Morningstar's "Cheap Stocks to Buy" list and announces a multiyear, $30 billion partnership with Apple for chip production.

9 jul 2026, 20:07 UTC

Correlated Moves
Social Media
News

Citibank's CIO survey shows Microsoft leads AI funding, with 69% from new budgets. Shares are trading higher amid positive sentiment and ongoing challenges.

9 jul 2026, 20:07 UTC

News
Correlated Moves

Ethereum sees $70 million in ETF inflows, the largest in 28 days. Despite negative social media sentiment, the asset is trading higher since Wednesday's close.

9 jul 2026, 20:07 UTC

Correlated Moves
News

Bitcoin rises to $63,300 as President Trump's comments ease geopolitical tensions. The Federal Reserve's policy review may also support investor confidence in the cryptocurrency.

9 jul 2026, 20:07 UTC

Correlated Moves
News

Bitcoin rises to $63,300 as President Trump's comments ease geopolitical tensions. The Federal Reserve's review of monetary policy may also boost investor confidence.

9 jul 2026, 20:07 UTC

News
Correlated Moves

Ethereum sees significant inflows of $70 million from ETFs, marking the largest daily increase in 28 days, contributing to its higher trading position since Wednesday.

9 jul 2026, 20:06 UTC

News

J B Hunt Transport Services is higher today after Goldman Sachs and Citigroup raised their price targets, reflecting positive assessments of the company's performance.

9 jul 2026, 20:06 UTC

News

MercadoLibre shares are lower as Bronstein, Gewirtz & Grossman, LLC announces an investigation into potential claims related to the company's financial practices.

9 jul 2026, 20:06 UTC

Social Media
News

Shares of Alphabet Inc. are lower amid concerns over its AI competitiveness, following a report suggesting Meta may surpass Google in frontier AI capabilities.

9 jul 2026, 20:06 UTC

Event
News
Social Media
Correlated Moves

Intuit Inc. shares rise as the company goes ex-dividend for $1.20. Investor interest grows amid overall market strength and positive sentiment in technology stocks.

9 jul 2026, 20:06 UTC

News
Correlated Moves

Geopolitical tensions following U.S. airstrikes on Iran have increased demand for safe-haven currencies, with CHF/HKD trading slightly higher during Thursday's session.

9 jul 2026, 20:03 UTC

News
Social Media
Event
Macro Event

PepsiCo Inc's stock is lower following mixed second-quarter earnings, with revenue at $24.18 billion but adjusted EPS of $2.20 missing estimates.

9 jul 2026, 20:02 UTC

News

Cisco Systems is trading higher as investors respond to its focus on smart building technology, including a partnership showing significant energy efficiency gains.

9 jul 2026, 20:02 UTC

Social Media
ETF Constituents
News

Invesco QQQ Trust trades higher, recovering above $713.75, as SpaceX's Nasdaq-100 inclusion boosts interest. Strong performances from Meta, Broadcom, and AMD support the ETF.

9 jul 2026, 20:02 UTC

Macro Event
News
Social Media
Correlated Moves

KLA shares advance as TD Cowen raises price target to $260. Positive sentiment in the semiconductor sector supports the upward movement amid increased AI demand.

Peer Vergelijking

Prijswijziging

Ovid therapeutics Inc Prognose

Koersdoel

By TipRanks

105.13% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 5.6 USD  105.13%

Hoogste 7 USD

Laagste 4 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ovid therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

7 ratings

7

Buy

0

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat